

# Christian Funck-Brentano

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7375271/christian-funck-brentano-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260  
papers

73,027  
citations

69  
h-index

270  
g-index

290  
ext. papers

84,228  
ext. citations

6.6  
avg, IF

6.32  
L-index

#	Paper	IF	Citations
260	Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database.. <i>Nature Communications</i> , <b>2022</b> , 13, 25	17.4	5
259	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19.. <i>Archives of Cardiovascular Diseases</i> , <b>2022</b> , 115, 96-96	2.7	
258	Coronary Angiographic Features and Major Adverse Cardiac or Cerebrovascular Events in People Living With Human Immunodeficiency Virus Presenting With Acute Coronary Syndrome.. <i>Circulation: Cardiovascular Interventions</i> , <b>2022</b> , 101161CIRCINTERVENTIONS122011945	6	0
257	Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> , 7, 312-320	6.4	17
256	Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2021</b> , 197, 113968	3.5	4
255	Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2021</b> , 59, 1800-1810	5.9	2
254	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. <i>Therapie</i> , <b>2021</b> , 76, 285-295	3.8	3
253	Ciprofloxacin population pharmacokinetics during long-term treatment of osteoarticular infections. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 2906-2913	5.1	2
252	Evaluation of Hydroxychloroquine Blood Concentrations and Effects in Childhood-Onset Systemic Lupus Erythematosus. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	3
251	Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. <i>European Heart Journal</i> , <b>2021</b> , 42, 3915-3928	9.5	6
250	Assessment of the Change of a Continuous Variable as a Function of its Initial Value. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1342	16.2	
249	Association of thyroid-stimulating hormone with corrected QT interval variation: A prospective cohort study among patients with type 2 diabetes. <i>Archives of Cardiovascular Diseases</i> , <b>2021</b> , 114, 656-666	2.7	1
248	Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome. <i>European Heart Journal</i> , <b>2021</b> , 42, 3948-3961	9.5	3
247	Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 166, 103342	7	5
246	Effect of congenital adrenal hyperplasia treated by glucocorticoids on plasma metabolome: a machine-learning-based analysis. <i>Scientific Reports</i> , <b>2020</b> , 10, 8859	4.9	0
245	Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 1-3	7.5	3
244	Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes. <i>PLoS ONE</i> , <b>2020</b> , 15, e0229145	3.7	5

243	Development and validation of a UPLC-MS/MS method for simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma: Application to the therapeutic drug monitoring in osteoarticular infections. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2020</b> , 183, 113-137	3.5	8
242	Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. <i>Archives of Cardiovascular Diseases</i> , <b>2020</b> , 113, 367-368	2.7	10
241	Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database. <i>Circulation</i> , <b>2020</b> , 142, 303-305	16.7	61
240	Results of the 2017 inspection campaign of French phase I/II research sites in Île-de-France following the BIA 10-2474 accident: Medical vs. regulatory relevance. <i>Therapie</i> , <b>2020</b> , 75, 517-525	3.8	
239	Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?. <i>Lancet, The</i> , <b>2020</b> ,	4.0	35
238	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , <b>2020</b> , 113, 9-21	2.7	15
237	Anti-ischæmic medication must be adapted to each patient's characteristics and preferences in patients with chronic coronary syndromes. <i>European Heart Journal</i> , <b>2020</b> , 41, 480-481	9.5	4
236	Uses of pharmacovigilance databases: An overview. <i>Therapie</i> , <b>2020</b> , 75, 591-598	3.8	37
235	Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. <i>Pharmaceuticals</i> , <b>2020</b> , 13,	5.2	5
234	HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017578	6	5
233	Circulating Receptor Activator of Nuclear Factor $\kappa$ B Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 140	8.7	8
232	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , <b>2020</b> , 41, 407-477	9.5	1835
231	Randomized study of the effect of gadopiclesol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 2174-2181	3.8	1
230	Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes <b>2020</b> , 15, e0229145		
229	Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes <b>2020</b> , 15, e0229145		
228	Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes <b>2020</b> , 15, e0229145		
227	Inactive matrix gla protein plasma levels are associated with peripheral neuropathy in Type 2 diabetes <b>2020</b> , 15, e0229145		
226	Cardiovascular Toxicities Associated With Ibrutinib. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1667-1678	15.1	85

225	Cardiac arrhythmia considerations of hormone cancer therapies. <i>Cardiovascular Research</i> , <b>2019</b> , 115, 878-894	9.9	33
224	Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. <i>Scientific Reports</i> , <b>2019</b> , 9, 883	4.9	6
223	Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation. <i>Scientific Reports</i> , <b>2019</b> , 9, 777	4.9	10
222	Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 141, 112-124	7	6
221	Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: Modeling and assessing interindividual variability. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1670-1682	15.4	15
220	Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy. <i>Diabetology and Metabolic Syndrome</i> , <b>2019</b> , 11, 32	5.6	6
219	Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. <i>Drug Safety</i> , <b>2019</b> , 42, 813-825	5.1	40
218	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , <b>2019</b> , 40, 87-165	9.5	2408
217	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2019</b> , 55, 4-90	3	251
216	Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes. <i>Circulation</i> , <b>2019</b> , 140, 1070-1080	16.7	49
215	Drug-induced aseptic meningitis: 329 cases from the French pharmacovigilance database analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2540-2546	3.8	11
214	Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , <b>2019</b> , 112, 699-712	2.7	12
213	Effects of Mineralocorticoid Receptor Antagonists on Atrial Fibrillation Occurrence: A Systematic Review, Meta-Analysis, and Meta-Regression to Identify Modifying Factors. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e013267	6	10
212	Plasma concentrations of dabrafenib and trametinib (PCD/T) monitoring in advanced BRAFV600mut melanoma patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9541-9541	2.2	1
211	Influence of hormones on the immunotolerogenic molecule HLA-G: a cross-sectional study in patients with congenital adrenal hyperplasia. <i>European Journal of Endocrinology</i> , <b>2019</b> , 181, 481-488	6.5	3
210	Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 476-482	3.2	10
209	P-glycoprotein influences urinary excretion of aldosterone in healthy individuals. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 2225-2231	1.9	3
208	Relation between baseline LDL-cholesterol and cardiovascular outcomes in high cardiovascular risk hypertensive patients: A post-hoc SPRINT data analysis. <i>International Journal of Cardiology</i> , <b>2019</b> , 286, 159-161	3.2	3

207	Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies. <i>Scientific Reports</i> , <b>2018</b> , 8, 1681	4.9	12
206	Complex Association of Sex Hormones on Left Ventricular Systolic Function: Insight into Sexual Dimorphism. <i>Journal of the American Society of Echocardiography</i> , <b>2018</b> , 31, 231-240.e1	5.8	11
205	Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. <i>Pharmacology &amp; Therapeutics</i> , <b>2018</b> , 189, 89-103	13.9	62
204	Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 877-882	16.2	18
203	Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. <i>Heart</i> , <b>2018</b> , 104, 1859-1863	5.1	29
202	Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. <i>Circulation</i> , <b>2018</b> , 138, 110-113	16.7	40
201	Inhibitor of Fatty Acid Amide Hydrolase - Learning from Tragic Failures. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 393-4	59.2	3
200	Comprehensive efforts to increase adherence to statin therapy. <i>European Heart Journal</i> , <b>2017</b> , 38, 2473-2479	34.9	29
199	Fast, accurate and easy-to-teach QT interval assessment: The triplicate concatenation method. <i>Archives of Cardiovascular Diseases</i> , <b>2017</b> , 110, 475-481	2.7	8
198	Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. <i>Journal of Thrombosis and Haemostasis</i> , <b>2017</b> , 15, 273-283	15.4	74
197	Effectiveness of heart rate control on hemodynamics in critically ill patients with atrial tachyarrhythmias managed by amiodarone. <i>Pharmacological Research</i> , <b>2017</b> , 122, 118-126	10.2	3
196	About fundamentals and sermonizers. Author response to the letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?". <i>Presse Medicale</i> , <b>2017</b> , 46, 352-353	2.2	1
195	Open letter on access to the BIA 10-2474 clinical trial data. <i>Lancet, The</i> , <b>2017</b> , 389, 156	40	11
194	Clinical pharmacology of anti-angiogenic drugs in oncology. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 119, 75-93	7	8
193	Impact of negative inotropic drugs on accuracy of diastolic stress echocardiography for evaluation of left ventricular filling pressure. <i>Scientific Reports</i> , <b>2017</b> , 7, 9537	4.9	4
192	Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. <i>American Heart Journal</i> , <b>2017</b> , 183, 91-101	4.9	18
191	GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, "GENEREPOl study": Lack of common variants with large effect sizes. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181875	3.7	10
190	Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. <i>ELife</i> , <b>2017</b> , 6,	8.9	61

189	Influence of steroid hormones on ventricular repolarization. <i>Pharmacology &amp; Therapeutics</i> , <b>2016</b> , 167, 38-47	13.9	50
188	Complex Influence of Gonadotropins and Sex Steroid Hormones on QT Interval Duration. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2776-84	5.6	34
187	Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2016</b> , 41, 125-38	2.7	9
186	Reply to the letter to the editor @lasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance@y Funck-Brentano et al. <i>Annals of Oncology</i> , <b>2016</b> , 27, 364-5	10.3	5
185	Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar. <i>Revista Espanola De Cardiologia</i> , <b>2016</b> , 69, 177.e1-177.e62	1.5	137
184	Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 991-1002	6.2	5
183	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. <i>American Journal of Cardiovascular Drugs</i> , <b>2016</b> , 16, 43-53	4	2
182	Determination of Colistin and Colistimethate Levels in Human Plasma and Urine by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 796-803	3.2	12
181	Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: application to a human pharmacokinetic study. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 132-6	3.2	8
180	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1470-5	10.3	37
179	Pharmacology and mechanisms of action of new oral anticoagulants. <i>Fundamental and Clinical Pharmacology</i> , <b>2015</b> , 29, 10-20	3.1	27
178	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , <b>2014</b> , 67, 136.e1-136.e56	1.5	8
177	Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2014</b> , 100, 230-235	3.5	29
176	Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. <i>Revista Espanola De Cardiologia</i> , <b>2014</b> , 67, 135.e1-135.e81	1.5	9
175	Grupo de Trabajo Conjunto sobre cirugía no cardíaca: Evaluación y manejo cardiovascular de la Sociedad Europea de Cardiología (ESC) y la European Society of Anesthesiology (ESA). <i>Revista Espanola De Cardiologia</i> , <b>2014</b> , 67, 1052.e1-1052.e43	1.5	3
174	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). <i>European Heart Journal</i> , <b>2014</b> , 35, 2393-424	9.5	849
173	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). <i>European Journal of Anaesthesiology</i> , <b>2014</b> , 31, 517-73	2.3	242
172	ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. <i>Diabetes and Vascular Disease Research</i> , <b>2014</b> , 11, 133-73	3.3	137

171	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: Impact on tumor response and tolerance.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9016-9016	2.2	
170	Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. <i>Archives of Cardiovascular Diseases</i> , <b>2013</b> , 106, 661-71	2.7	14
169	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , <b>2013</b> , 34, 3035-87	9.5	1444
168	Guía de práctica clínica sobre el tratamiento de las valvulopatías (versión 2012). <i>Revista Espanola De Cardiologia</i> , <b>2013</b> , 66, 131.e1-131.e42	1.5	
167	Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012: Actualización de las guías de la Sociedad Europea de Cardiología (ESC) para el manejo de la fibrilación auricular de 2010 Elaborada en colaboración con la Asociación Europea del Ritmo Cardíaco. <i>Revista Espanola De Cardiologia</i> , <b>2013</b> , 66, 54.e1-54.e24	1.5	10
166	Guía de práctica clínica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. <i>Revista Espanola De Cardiologia</i> , <b>2013</b> , 66, 53.e1-53.e46	1.5	17
165	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2013</b> , 34, 2159-219	9.5	3400
164	2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2013</b> , 34, 2949-3003	9.5	3076
163	Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers. <i>Hypertension</i> , <b>2013</b> , 61, 1239-45	8.5	8
162	How can the quality of medical data in pharmacovigilance, pharmacoepidemiology and clinical studies be guaranteed?. <i>Therapie</i> , <b>2013</b> , 68, 209-23	3.8	3
161	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for	9.5	15
160	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. <i>Europace</i> , <b>2012</b> , 14, 1385-413	3.9	1019
159	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , <b>2012</b> , 33, 2451-96	9.5	2866
158	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 863-69	12.3	1892
157	Third universal definition of myocardial infarction. <i>Nature Reviews Cardiology</i> , <b>2012</b> , 9, 620-33	14.8	146
156	Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Journal of Cardio-thoracic Surgery</i> , <b>2012</b> , 42, S1-44	3	1002
155	Third universal definition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 1581-98	15.1	2143
154	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardíaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , <b>2012</b> , 65, 938.e1-938.e59	1.5	27

153	2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <i>European Heart Journal</i> , <b>2012</b> , 33, 2719-47	9.5	2638
152	In vitro cardiovascular effects of dihydroartemisin-piperazine combination compared with other antimalarials. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 3261-70	5.9	40
151	Third universal definition of myocardial infarction. <i>Circulation</i> , <b>2012</b> , 126, 2020-35	16.7	2259
150	Effects of oxytocin on Purkinje fibres. <i>British Journal of Anaesthesia</i> , <b>2012</b> , 108, 1039-41	5.4	3
149	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , <b>2012</b> , 33, 1787-847	9.5	3691
148	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , <b>2012</b> , 33, 2569-619	9.5	3978
147	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , <b>2012</b> , 33, 2551-67	9.5	2064
146	Conflicts of interests in the area of healthcare products and technology. Current state of affairs and recommendations. <i>Therapie</i> , <b>2012</b> , 67, 289-94	3.8	0
145	ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2011</b> , 32, 3147-97	9.5	1167
144	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , <b>2011</b> , 32, 1769-818	9.5	2020
143	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2011</b> , 32, 2851-906	9.5	1126
142	Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial. <i>Cardiovascular Therapeutics</i> , <b>2011</b> , 29, 89-98	3.3	14
141	Effects of HIV protease inhibitors on cardiac conduction velocity in unselected HIV-infected patients. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 442-8	6.1	7
140	Human plasma quantification of droperidol and ondansetron used in preventing postoperative nausea and vomiting with a LC/ESI/MS/MS method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2011</b> , 879, 186-90	3.2	7
139	Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 765-72	12.3	23
138	Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. <i>European Heart Journal</i> , <b>2011</b> , 32, 41-50	9.5	76
137	2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 1143-53	12.3	118
136	2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>Europace</i> , <b>2010</b> , 12, 1526-36	3.9	158



135	Guidelines on myocardial revascularization. <i>European Heart Journal</i> , <b>2010</b> , 31, 2501-55	9.5	2070
134	2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>European Heart Journal</i> , <b>2010</b> , 31, 2291-300	9.5	335
133	Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>Europace</i> , <b>2010</b> , 12, 1360-420	3.9	1120
132	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). <i>European Journal of Anaesthesiology</i> , <b>2010</b> , 26, 100-10	2.3	158
131	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2047-54		61
130	Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 610-3	15.4	32
129	Can we override clopidogrel resistance?. <i>Circulation</i> , <b>2009</b> , 119, 2854-7	16.7	95
128	Effects of testosterone on ventricular repolarization in hypogonadic men. <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 887-90	3	70
127	Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. <i>British Journal of Clinical Pharmacology</i> , <b>2009</b> , 67, 76-82	3.8	37
126	Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. <i>British Journal of Clinical Pharmacology</i> , <b>2009</b> , 67, 511-9	3.8	47
125	Droperidol and ondansetron in vitro electrophysiological drug interaction study. <i>Fundamental and Clinical Pharmacology</i> , <b>2009</b> , 23, 719-26	3.1	16
124	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation. <i>European Respiratory Journal</i> , <b>2009</b> , 33, 1780-91	9.5	2531
123	Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Antimicrobials. <i>European Heart Journal</i> , <b>2009</b> , 30, 2369-319	9.5	1415
122	Guidelines for the diagnosis and management of syncope (version 2009). <i>European Heart Journal</i> , <b>2009</b> , 30, 2631-71	9.5	1408
121	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. <i>Lancet, The</i> , <b>2009</b> , 373, 309-17	40	755
120	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , <b>2009</b> , 30, 2769-812	9.5	545
119	Therapeutic drug monitoring of clozapine in a hemodialysed smoking patient with schizophrenia. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 281-2	3.2	5
118	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2008</b> , 29, 2909-45	9.5	1774

117	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Journal of Anaesthesiology</i> , <b>2008</b> , 109, 206-12	12.3	1355
116	Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. <i>Anesthesiology</i> , <b>2008</b> , 109, 206-12	4.3	92
115	Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2008</b> , 29, 2276-315	9.5	2125
114	Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 81, 679-84	6.1	49
113	European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2007</b> , 14 Suppl 2, S1-113		751
112	2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , <b>2007</b> , 25, 1105-87	1.9	3825
111	Universal definition of myocardial infarction. <i>Circulation</i> , <b>2007</b> , 116, 2634-53	16.7	1953
110	Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. <i>Rheumatology</i> , <b>2007</b> , 46, 808-10	1.9	90
109	Droperidol-induced proarrhythmia: the beginning of an answer?. <i>Anesthesiology</i> , <b>2007</b> , 107, 524-6	4.3	8
108	2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Blood Pressure</i> , <b>2007</b> , 16, 135-232	1.7	247
107	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2007</b> , 14 Suppl 2, S1-113		309
106	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2007</b> , 28, 1462-536	9.5	1418
105	Beta-blockade in CHF: from contraindication to indication. <i>Country Review Ukraine</i> , <b>2006</b> , 8, C19-C27		13
104	Prolonged ventricular repolarization in hypertension: is it heart rate?. <i>Archives of Internal Medicine</i> , <b>2006</b> , 166, 2157; author reply 2157-8		
103	Poor ex vivo induction of T-cell responses to idiotypic or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 1340-7	1.9	4
102	Postoperative analgesia and recovery course after major colorectal surgery in elderly patients: a randomized comparison between intrathecal morphine and intravenous PCA morphine. <i>Regional Anesthesia and Pain Medicine</i> , <b>2006</b> , 31, 531-8	3.4	13
101	Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. <i>Lung Cancer</i> , <b>2006</b> , 54, 11-8	5.9	37
100	3-Hydroxybenzo[a]pyrene in the urine of smokers and non-smokers. <i>Toxicology Letters</i> , <b>2006</b> , 162, 181-5	4.4	47

99	QT interval measurement: evaluation of automatic QTc measurement and new simple method to calculate and interpret corrected QT interval. <i>Anesthesiology</i> , <b>2006</b> , 104, 255-60	4.3	64
98	Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others". <i>European Journal of Heart Failure</i> , <b>2006</b> , 8, 219-20	12.3	2
97	Postoperative Analgesia and Recovery Course After Major Colorectal Surgery in Elderly Patients. <i>Regional Anesthesia and Pain Medicine</i> , <b>2006</b> , 31, 531-538	3.4	32
96	Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. <i>Anesthesiology</i> , <b>2005</b> , 102, 1094-100	4.3	206
95	Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. <i>Blood</i> , <b>2005</b> , 106, 135-40	2.2	301
94	Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy women. <i>British Journal of Clinical Pharmacology</i> , <b>2005</b> , 60, 120-7	3.8	9
93	Corrected QT interval in anti-SSA-positive adults with connective tissue disease: comment on the article by Lazzerini et al. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 676-7; author reply 677-8		25
92	Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 821-9	2.8	43
91	Pharmacogenetics of acenocoumarol pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 75, 403-14	6.1	42
90	QT interval prolongation after oxytocin bolus during surgical induced abortion. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 359-64	6.1	38
89	Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). <i>European Heart Journal</i> , <b>2003</b> , 24, 552-9	9.5	87
88	Influence of endogenous oestrogens on QT interval duration. <i>European Heart Journal</i> , <b>2003</b> , 24, 1663-7	9.5	46
87	Cardiovascular safety of salmeterol in COPD. <i>Chest</i> , <b>2003</b> , 123, 1817-24	5.3	81
86	Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 73, 242-52	6.1	32
85	Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 73, 51-60	6.1	65
84	Genetic and environmental risk factors for oral anticoagulant overdose. <i>European Journal of Clinical Pharmacology</i> , <b>2003</b> , 58, 739-45	2.8	35
83	Digoxin pharmacokinetics and MDR1 genetic polymorphisms. <i>European Journal of Clinical Pharmacology</i> , <b>2003</b> , 58, 809-12	2.8	124
82	Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. <i>Fundamental and Clinical Pharmacology</i> , <b>2003</b> , 17, 373-6	3.1	61

81	Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 488-95	6.1	42
80	Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 468-78	6.1	5
79	Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 112-22	6.1	23
78	Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 391-402	6.1	79
77	The role of the critical event committee in a major cardiovascular outcome study. <i>Blood Pressure</i> , <b>2002</b> , 11, 339-44	1.7	10
76	Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 72, 514-23	6.1	42
75	Is diclofenac a valuable CYP2C9 probe in humans?. <i>European Journal of Clinical Pharmacology</i> , <b>2001</b> , 56, 793-7	2.8	60
74	Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>2001</b> , 52, 601-4	3.8	39
73	Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 70, 311-316	6.1	53
72	Comparison of sympathetic modulation induced by single oral doses of mibefradil, amlodipine, and nifedipine in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 69, 122-9	6.1	10
71	Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). <i>European Heart Journal</i> , <b>2001</b> , 22, 1021-31	9.5	28
70	Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). <i>Circulation</i> , <b>2001</b> , 103, 375-80	16.7	220
69	Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). <i>American Heart Journal</i> , <b>2001</b> , 142, 989-97	4.9	10
68	Steady-state versus non-steady-state QT-RR relationships in 24-hour Holter recordings. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>2000</b> , 23, 293-302	1.6	30
67	Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. <i>Fundamental and Clinical Pharmacology</i> , <b>2000</b> , 14, 519-25	3.1	21
66	Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 67, 432-7	6.1	94
65	Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 68, 658-66	6.1	120
64	Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): A study of the interactions between $\beta$ -blocker therapy and occurrence of critical events using analysis of competitive risks. <i>American Heart Journal</i> , <b>2000</b> , 139, 262-271	4.9	6

63	Predictors of medical events in patients enrolled in the cardiac insufficiency bisoprolol study (CIBIS): a study of the interactions between beta-blocker therapy and occurrence of critical events using analysis of competitive risks. <i>American Heart Journal</i> , <b>2000</b> , 139, 262-71	4.9	8
62	Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>1999</b> , 48, 453-6	3.8	18
61	A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>1999</b> , 47, 49-52	3.8	16
60	Effects of cigarette smoking on short-term variability of blood pressure in smoking and non smoking healthy volunteers. <i>Fundamental and Clinical Pharmacology</i> , <b>1999</b> , 13, 501-7	3.1	14
59	Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics. <i>Fundamental and Clinical Pharmacology</i> , <b>1999</b> , 13, 232-6	3.1	17
58	Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 66, 582-8	6.1	14
57	Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1998</b> , 64, 192-203	6.1	121
56	Dynamic analysis of dofetilide-induced changes in ventricular repolarization. <i>Clinical Pharmacology and Therapeutics</i> , <b>1998</b> , 64, 312-21	6.1	26
55	Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. <i>Pharmacogenetics and Genomics</i> , <b>1998</b> , 8, 101-8		27
54	Glutathione S-transferase theta genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer® patients. <i>Pharmacogenetics and Genomics</i> , <b>1997</b> , 7, 251-3		10
53	Repeatability of spectral components of short-term blood pressure and heart rate variability during acute sympathetic activation in healthy young male subjects. <i>Clinical Science</i> , <b>1997</b> , 93, 21-8	6.5	22
52	Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>1997</b> , 44, 403-9	3.8	14
51	Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>1997</b> , 61, 619-27	6.1	44
50	Assessment of CYP2D6 activity in very elderly healthy subjects. <i>Fundamental and Clinical Pharmacology</i> , <b>1996</b> , 10, 158-9	3.1	4
49	Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. <i>Clinical Pharmacology and Therapeutics</i> , <b>1996</b> , 59, 583-92	6.1	26
48	Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>1996</b> , 41, 499-503	3.8	37
47	Influence of liver cirrhosis on sertraline pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , <b>1996</b> , 42, 394-7	3.8	29
46	Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. <i>Circulation</i> , <b>1996</b> , 94, 1592-9	16.7	50

45	Are intracardiac electrophysiological studies in healthy volunteers ethical? Time for multinational recommendations. <i>Journal of Cardiovascular Pharmacology</i> , <b>1995</b> , 26, 524-7	3.1	3
44	Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>1995</b> , 58, 257-63	6.1	14
43	Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. <i>Clinical Pharmacology and Therapeutics</i> , <b>1995</b> , 57, 533-42	6.1	54
42	Comparison of tolerance to intravenous nitroglycerin during nicorandil and intermittent nitroglycerin patch in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 56, 672-9	6.1	6
41	Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. <i>Clinical Pharmacology and Therapeutics</i> , <b>1994</b> , 55, 256-69	6.1	66
40	Clinical evaluation of pain during subcutaneous injections of low molecular weight heparins in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>1994</b> , 37, 395-7	3.8	5
39	Reproducibility of non-invasive measurement and of short-term variability of blood pressure and heart rate in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>1994</b> , 38, 109-15	3.8	17
38	Rapid Development of Nitrate Tolerance in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , <b>1994</b> , 24, 266-273	3.1	9
37	Relationships between acute and chronic beta-blocking effects of bisoprolol in healthy volunteers: a practical approach to predict intensity of beta-blockade. <i>Journal of Cardiovascular Pharmacology</i> , <b>1994</b> , 23, 658-63	3.1	2
36	Rapid Development of Nitrate Tolerance in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology</i> , <b>1994</b> , 24, 266-273	3.1	5
35	Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. <i>British Journal of Clinical Pharmacology</i> , <b>1993</b> , 36, 531-8	3.8	15
34	Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol. <i>European Heart Journal</i> , <b>1993</b> , 14 Suppl H, 30-5	9.5	150
33	Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. <i>Journal of Cardiovascular Pharmacology</i> , <b>1993</b> , 22, 711-6	3.1	43
32	CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. <i>Pharmacogenetics and Genomics</i> , <b>1993</b> , 3, 197-204		122
31	d-sotalol reduces heart rate in vivo through a beta-adrenergic receptor-independent mechanism. <i>Clinical Pharmacology and Therapeutics</i> , <b>1993</b> , 53, 436-42	6.1	14
30	Rate-corrected QT interval: techniques and limitations. <i>American Journal of Cardiology</i> , <b>1993</b> , 72, 17B-22B		288
29	Rate-dependence of class III actions in the heart. <i>Fundamental and Clinical Pharmacology</i> , <b>1993</b> , 7, 51-9	3.1	13
28	Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>1992</b> , 51, 507-12	6.1	26

27	The pharmacokinetics of perindopril in patients with liver cirrhosis. <i>British Journal of Clinical Pharmacology</i> , <b>1992</b> , 33, 326-8	3.8	24
26	Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>1992</b> , 52, 384-93	6.1	48
25	Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1992</b> , 52, 417-26	6.1	33
24	Influence of amiodarone on genetically determined drug metabolism in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 50, 259-66	6.1	22
23	Prospective pharmacokinetically based development of effective infusion regimens for ACC-9358, a new antiarrhythmic drug. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 49, 314-21	6.1	1
22	Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. <i>Clinical Pharmacology and Therapeutics</i> , <b>1991</b> , 49, 488-96	6.1	10
21	Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. <i>Circulation</i> , <b>1991</b> , 83, 536-45	16.7	66
20	Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. <i>Clinical Pharmacology and Therapeutics</i> , <b>1990</b> , 47, 397-402	6.1	30
19	Concentration/response relations for the multiple antiarrhythmic actions of sotalol. <i>American Journal of Cardiology</i> , <b>1990</b> , 65, 22A-27A; discussion 35A-36A	3	29
18	Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris. <i>American Journal of Cardiology</i> , <b>1990</b> , 66, 812-7	3	18
17	Propafenone. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 518-25	59.2	121
16	The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 1764-8	59.2	133
15	Stereoselective disposition and pharmacologic activity of propafenone enantiomers. <i>Circulation</i> , <b>1989</b> , 79, 1068-76	16.7	102
14	Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids. <i>Biomedical Applications</i> , <b>1989</b> , 490, 165-74		2
13	Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias. <i>Clinical Pharmacology and Therapeutics</i> , <b>1989</b> , 46, 324-34	6.1	5
12	Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. <i>British Journal of Clinical Pharmacology</i> , <b>1989</b> , 27, 435-44	3.8	56
11	Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. <i>Journal of Cardiovascular Pharmacology</i> , <b>1989</b> , 14, 364-73	3.1	16
10	Topics in clinical pharmacology: buspirone: a new nonbenzodiazepine anxiolytic agent. <i>American Journal of the Medical Sciences</i> , <b>1989</b> , 297, 49-52	2.2	3

9	Overview of the clinical pharmacology of antiarrhythmic drugs. <i>American Journal of Cardiology</i> , <b>1988</b> , 61, 61A-69A	3	17
8	Rate dependence of ventricular extrasystoles: computer identification and quantitative analysis. <i>Cardiovascular Research</i> , <b>1988</b> , 22, 101-7	9.9	14
7	Encainide: a useful new antiarrhythmic drug. <i>American Journal of the Medical Sciences</i> , <b>1988</b> , 296, 76-7	2.2	
6	Effect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in man. <i>British Journal of Clinical Pharmacology</i> , <b>1987</b> , 24, 559-60	3.8	4
5	Drug interactions and hepatitis produced by some macrolide antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1985</b> , 16 Suppl A, 181-94	5.1	100
4	Regulation of renal cytochrome P-450. Effects of two-thirds hepatectomy, cholestasis, biliary cirrhosis and post-necrotic cirrhosis on hepatic and renal microsomal enzymes. <i>Biochemical Pharmacology</i> , <b>1985</b> , 34, 311-20	6	38
3	Protective effect of 16,16-dimethyl prostaglandin E2 on the hepatotoxicity of bromobenzene in mice. <i>Biochemical Pharmacology</i> , <b>1984</b> , 33, 89-96	6	26
2	Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. <i>Biochemical Pharmacology</i> , <b>1983</b> , 32, 1063-8	6	103
1	Hepatotoxicity of Trichloroethylene-Carbon Tetrachloride Mixtures in Rats. <i>Gastroenterology</i> , <b>1982</b> , 83, 761-772	13.3	37